Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Thiogenesis Therapeutics Corp., a clinical-stage biopharmaceutical company, has engaged Capital Analytica for investor relations services to enhance social media presence and investor engagement. The company agreed to pay quarterly fees and grant stock options under the new agreement. Additionally, Thiogenesis has issued restricted share units to an officer, with both stock options and RSUs subject to regulatory approval.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
